#4-54E. Targeting Remission: Treat-to-Target vs Symptom-Driven Gout Care (Lancet Rheumatol, 2026)

Should clinicians proactively monitor and titrate urate levels in gout patients, or simply manage their symptoms as they arise? In today's episode, we examine the landmark GO TEST Overture trial, a multicenter, open-label randomized controlled trial comparing a treat-to-target strategy—aiming for a serum urate target of less than 0.36 mmol/L—against conventional symptom-driven management1. The most critical finding is that the treat-to-target approach significantly improves long-term remission rates and overall disease control without increasing the frequency of adverse events. However, when critically appraising these results, listeners must consider the study's open-label design, which inherently risks introducing performance and reporting biases, particularly concerning subjective patient-reported outcomes like pain scores. Despite this limitation, this paper is exceptionally essential for our clinical audience because it provides robust, pragmatic evidence that directly addresses existing guideline conflicts. Ultimately, it underscores the vital importance of systematic urate-lowering therapy titration and continuous monitoring in everyday clinical practice to ensure effective and sustainable gout management.

Citation: Moses, Anusha, and Jansen, Tim L. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial. Lancet Rheumatology. 2026. DOI: 10.1016/S2665-9913(26)00034-2

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.